Background: Some evidence-based bundles have tried to standardize the management of Staphylococcus aureus bacteraemia (SAB) to improve the outcome. The aim of our study was to analyse the additional impact on mortality of a structured intervention in patients with SAB.
Introduction
Staphylococcus aureus is one of the main causes of bacteraemia, both community acquired and healthcare associated, with an incidence ranging between 4 and 40 per 100 000 persons/year. [1] [2] [3] Despite the availability of new drugs or combinations of drugs highly active against S. aureus, 30 day mortality in patients with S. aureus bacteraemia (SAB) remains high at 15%-30%. [4] [5] [6] [7] Factors found to be associated with increased mortality rates among patients with SAB are methicillin resistance, 4, 8 advanced age, 4, 8 comorbidities (renal failure, cirrhosis), 4, 8 ICU admission 4, 8 and delay in the initiation of an appropriate treatment. 5, 9 Management of SAB is complex. Although recently published guidelines 10, 11 have issued recommendations for the proper management of SAB, compliance with these recommendations in clinical practice is far from optimal. Previous studies have shown that consultation with an infectious diseases specialist (IDS) improves treatment of these patients, 4, 9, 12 decreases the risk of recurrence 13 and reduces mortality. 4, 5, 7, 8, [12] [13] [14] [15] [16] Evidence-based quality indicators for the management of SAB have been identified and adherence to them is associated with better outcomes. 6, [16] [17] [18] However, achieving high adherence is difficult and compliance is very heterogeneous, depending on the centre and the type of indicator. 4, 6, 18 Although consultation with an IDS improves adherence, 16 this may depend on the IDS's individual performance and therefore its generalizability may be limited. Therefore, the present question is not whether IDS consultations should be implemented for SAB in all hospitals, but how IDS consultations should work so that adherence to quality indicators is improved. A structured intervention based on the indicators showed good results in a multicentre study 6 and was also validated in a community centre. 19 However, it is still important to investigate whether such an intervention is applicable and efficacious in other large hospitals.
The fact that a simple IDS active consultation and the structured intervention based on quality indicators were sequentially implemented in Complexo Hospitalario Universitario de Vigo (CHUVI) provides us with the opportunity to evaluate the impact of both types of activities. The objective of this study was to analyse the impact of two interventions (IDS active consultation and structured intervention) on the compliance with evidence-based indicators in patients with SAB and their additional impact on 14 and 30 day crude mortality rates. The secondary endpoint was to estimate the time required in the follow-up of patients with SAB.
Materials and methods
CHUVI is a 1153 bed, university hospital that serves a population of 564 452 inhabitants. The hospital was restructured in August 2015. Before this date, there were two separate buildings, one with a bacteraemia programme (BP) and the other one without (no-BP). After the restructuring, all admitted patients with SAB were consulted by the same IDS. The gap between retrospective and prospective periods was a consequence of delays in getting hospital ethical review board approval and we excluded the data for January 2015-May 2016 as this was considered a transitional period.
All episodes of SAB in adult patients (18 years) were evaluated. In patients with more than one episode of bacteraemia occurring within 3 months after finalization of therapy for the previous episode, only the former episode was included. Patients who died within 48 h from the extraction of the first set of blood cultures and those currently receiving palliative care were excluded. We considered patients receiving palliative care as those who did not receive active therapy against the infection owing to their poor basal clinical situation.
Compliance with the recommended bundle of care was determined by comparing three groups of patients (Table 1 ). In the first (no-BP group), patients with SAB between January 2013 and December 2014 were retrospectively collected. In this group, physicians in charge of patients were informed via telephone by the microbiologists when a blood culture was positive; no other intervention was performed. The second group (BP group) included the patients with SAB between January 2013 and December 2014, and data were also collected retrospectively. In this case, a multidisciplinary team composed of one microbiologist and two IDS consultants who met daily from Monday to Friday provided unsolicited consultations to all patients with SAB. Positive blood cultures were reviewed and therapeutic or diagnostic recommendations were made to physicians in charge according to IDS criteria. In order to find the source of the infection or to rule out complications, physical examination was performed by an IDS. Finally, the third group [structured intervention and bacteraemia programme group (i-BP)] consisted of patients with SAB between June 2016 and August 2017 for whom an intervention consisting of a set of structured written recommendations in the electronic medical history and personal contact was performed; the recommendations followed the six variables previously identified as quality of care for SAB: 6 follow-up blood cultures, early source control, transoesophageal echocardiography in patients with complicated bacteraemia (defined below), early use of intravenous cloxacillin or cefazolin for MSSA (defined as definitive therapy started within the first 24 h after methicillin susceptibility was confirmed), adjustment of vancomycin dose according to trough levels and treatment duration of at least 14 days for uncomplicated bacteraemia and 28 days for complicated bacteraemia. Also, physical examination was performed by an IDS when it was needed to find the source of the infection or to rule out complications.
Complicated bacteraemia was defined as persistent bacteraemia, peripheral embolisms, intravascular devices (e.g. cardiovascular implantable electronic device, prosthetic valve) or patients with SAB of unknown source, especially in those with infection that is community acquired. 20 To calculate the compliance of this variable, we looked at the proportion between patients who had an echocardiography performed and those with indication for performing an imaging study.
Finally, the bundle compliance rate was calculated by dividing the total number of variables performed in a patient by the total number of indicated variables in this patient.
The number of visits and time spent on them were recorded only in patients attended outside the infectious disease unit. A record of each of the visits was taken. For the first assessment of patients, with review of medical history and contact with the clinician responsible for the patient, a time of 30 min was assigned to each patient. Time required for follow-up visits was 10 min.
Ethics
This study was approved by the local ethics committee (approval code: 2016/078). Informed consent was not required.
Variables and definitions
The main outcome variable was compliance with the six individual activities included in the recommended bundle as specified above. Secondary outcomes were 14 and 30 day all-cause mortality, clinical cure and recurrence.
The Charlson comorbidity index was used to measure the severity of underlying chronic diseases. 21 Acute infection severity was assessed using the Pitt bacteraemia score, 22 measured on the day before SAB diagnosis. The type of SAB infection was classified as community acquired, healthcare associated or nosocomial, according to Friedman criteria. 23 Persistent bacteraemia was defined as S. aureus isolation in peripheral blood cultures after 72 h on adequate antibiotic treatment. Patients were considered to have complicated bacteraemia if they met any of the following criteria: persistent bacteraemia; endocarditis; presence of septic emboli, Janeway lesions, Osler nodes, mucosal or skin lesions suggestive of acute infection (petechiae, vasculitis, bruising, pustules, Roth's spots, conjunctival haemorrhage) in the absence of another cause; intravascular device infection where the device could not be removed within 3 days following SAB diagnosis; carriers of permanent prosthetic medical devices; and patients on haemodialysis.
Empirical antibiotic treatment was classified as adequate when it was initiated within 24 h of drawing blood samples for culture and the regimen included at least one active drug, according to in vitro susceptibility tests. The following regimens were considered adequate for the treatment of MSSA infection: intravenous cloxacillin 2 g/4 h, cefazolin 2 g/8 h and daptomycin 6-10 mg/kg once daily. Cefazolin 2 g intravenously, administered at the end of each session, was also accepted as appropriate in patients on haemodialysis. Adequate treatment for MRSA infection included: intravenous vancomycin 15-20 mg/kg/day (adjusted to achieve a trough level of 15-20 mg/mL); daptomycin 6-10 mg/kg/day (excluding patients with pneumonia); and intravenous or oral linezolid 600 mg/12 h.
Compliance with the bundle was considered appropriate when .75% of applicable individual measures were followed.
Clinical cure was defined as absence of signs and symptoms of infection and negative blood cultures during treatment. Recurrence was defined as the isolation of a phenotypically identical S. aureus from blood cultures Pérez-Rodríguez et al.
and/or from a deep-seated focus within 3 months following discontinuation of antibiotic treatment. The follow-up was carried out by reviewing the integrated (hospital and primary assistance) electronic clinical history.
The number of visits and time required to attend to patients outside the infectious disease unit were collected.
Statistical analysis
Comparison of percentages was performed using v 2 or Fisher's exact test, and Students t-test or Mann-Whitney test was used for continuous variables. Relative risks with 95% CI were calculated. Logistic regression was used to determine the influence of the independent variables on 14 and 30 day mortality. Variables introduced in the model were those that in univariate analysis showed a P value ,0.2.
Statistical analysis was performed using statistical package SPSS v24.
Results
Overall, 296 episodes of SAB were identified. Twenty-five episodes were excluded: 21 patients died within the first 48 h of diagnosis and 4 patients received only palliative care. Therefore, 271 patients were included in the final analysis. A total of 188 were included in the retrospective part (107 no-BP group and 81 BP group) and 83 in the intervention part of the study (i-BP). The characteristics of patients included in the study are shown in Table 2 . Demographics, comorbidities and acquisition types were similar among the three groups. There were some differences across groups regarding source of infection, proportion of MRSA and ICU admission.
The compliance with almost all components of the management bundle was significantly higher in the BP and i-BP groups (Table 3 ). In the i-BP group, the median number of visits performed by the IDS was three [IQR 2-3, first visit (30 min) and two follow-up visits (10 min each)] and the median time required per visit was 50 min (IQR 40-55 min). Over the three groups, the clinical cure rate increased (no-BP 79% versus BP 86% versus i-BP 93%, P " 0.021); however, differences between groups were not detected. Recurrence was similar in the three periods (no-BP 3% versus BP 4% versus i-BP 7%, P " 0.341). The mortality rate decreased significantly among the three groups at 14 days (no-BP 18% versus BP 7% versus i-BP 2%, P " 0.002) and at 30 days (no-BP 20% versus BP 12% versus i-BP 5%, P " 0.011).
Univariate analysis of factors related to 14 and 30 day mortality are shown in Table 4 . The factors associated with 14 day mortality in multivariate analysis were heart failure (OR " 7.63, 95% CI 2.82-20.64, P , 0.001), MRSA infection (OR " 4.02, 95% CI 1.52-10.61, P " 0.005) and persistent bacteraemia (OR " 11.01, 95% CI 2.63-46.04, P " 0.001); catheter-related bacteraemia (OR " 0.16, 95% CI 0.04-0.79, P " 0.023) and .75% bundle compliance (OR " 0.15, 95% CI 0.05-0.50, P " 0.002) were protective factors. Thirty-day mortality was related to heart failure (OR " 2.27, 95% CI 2.11-13.18, P " 0.001), persistent bacteraemia (OR " 7.83, 95% CI 2.25-27.29, P " 0.001) and MRSA infection (OR " 4.37, 95% CI 1.84-10.38, P " 0.001), whereas catheter-related bacteraemia (OR " 0.19, 95% CI 0.03-0.53, P " 0.005) and .75% bundle compliance (OR " 0.199, 95% CI 0.07-0.54, P " 0.002) were protective factors.
Discussion
The results of this study confirm that higher compliance with quality-of-care indicators in the management of SAB is associated with (21) 12 (14) 0.025 Pitt score, median (IQR) 0 (0-2) 1 (0-3) 0 (0-2) 0.043 ICU admission, n (%) 9 (8) 18 (22) 14 (17) Impact of a structured intervention on mortality in SAB JAC lower mortality. Adherence is improved when consultation by an IDS is provided to all patients with SAB, but even more if the IDS uses a structured procedure to provide the recommendations based on a bundle of actions.
A number of studies conducted on patients with SAB have demonstrated the impact of IDS consultation on reduction of SABassociated mortality. 4, 5, 7, 11, 12, 24 In our study, this result was also observed; mortality in the BP group decreased dramatically compared with the no-BP group. However, after the implementation of a structured intervention, 14 and 30 day mortality rates were even lower. This was related to higher compliance with the bundles of management that previously have been proved to reduce the mortality of patients with SAB. 6 Our results show that a structured intervention is associated with an increase in compliance (.75% from 20% in non-BP to 90% in i-BP, P , 0.001). We think that the improvement in compliance was directly related to the intervention. During the BP period the IDS complied with a high percentage of the quality-of-care components, similar to the intervention period of López-Cortés et al. 6 However, during the i-BP, we observed an increase in compliance with the bundles. We think that performing structured recommendations, which were written in the electronic medical history, helped to obtain this improvement.
Recently a randomized clinical trial analysed the effect of an algorithm-based therapy on clinical success and side effects in patients with staphylococcal bacteraemia. 25 This work did not show differences in management of patients with uncomplicated SAB. However, in patients with CoNS bacteraemia, the duration of therapy was lower. This shows that a standardized treatment contributes to better management of patients. Also, Nagao et al. 26 observed a reduction in mortality in patients with SAB when the adherence to evidence-based quality-of-care indicators increased. In that study mortality at 30 days was reduced from 10% to 3.4%. Their results are notable for the high percentage of patients with MRSA infections (41.7%).
A retrospective analysis of evidence-based bundles observed more adequate and earlier treatment in patients with SAB, with a reduction in hospital admissions, but without an impact on mortality. 25 However, another retrospective study detected that increasing the evidence-based application of the care process lowered mortality. 18 In our work, compliance with the bundle was higher in the structured intervention group. Moreover, this is the first study to find that a compliance .75% is a factor that reduces mortality in addition to the simple provision of the bundle.
An interesting finding is that the intervention takes very little time for each patient; in only 50 min (a first visit of 30 min and two follow-up visits of 10 min each) the outcomes for these patients can be improved. To the best of our knowledge, this is the first study analysing this aspect. We believe that it is an important finding because it provides useful information for the applicability of the intervention in any hospital, considering its significant impact on the mortality of patients with SAB.
In our study, we detected differences between the three groups that could influence mortality and therefore might be confounders for the effect of the interventions. First, a different rate of MRSA infection: MRSA has been associated with increased mortality in some studies. 4, [27] [28] [29] Over the three groups we found a significant decrease in MRSA infections between no-BP, BP and i-BP. Also, the source of infection was diverse. Catheter-related bacteraemia, which is associated with lower mortality, 6 was higher in i-BP whereas other high-risk sources of bacteraemia, such as pneumonia or unknown origin, 6, 30 were lower in i-BP. We cannot discard that some of these differences were in fact due to a better identification of the source of infection in the last phase of the study. Although all these variables were controlled in multivariable analysis and .75% compliance remained a statistically independent factor related to lower mortality, a potential effect of residual confounding cannot be ruled out. Pérez-Rodríguez et al.
Nevertheless, in the intervention period, we observed very low mortality (5%) at 30 days. This is a very surprising result that cannot be explained by the characteristics of patients in this period. Such an effect was also found in a previous study. 26 We believe that different factors might be involved and one of them could be a better compliance with the care bundle.
In this study, cefazolin 2 g/8 h was considered an adequate treatment. Recently numerous studies have demonstrated that it is a safe treatment option in patients with non-complicated SAB. [31] [32] [33] [34] We only used cefazolin in catheter-related bacteraemia and also in patients with other sources of infection after achieving negative blood cultures.
However, this study has some limitations. The first is that the work was performed in a single centre and the number of patients included in each group is low. Also, the interventions were not randomized, but we used multivariate analyses to control for the effect of confounders. The somehow restrictive policy to perform transoesophageal echocardiograms in our practice could have led to an underdiagnosis of endocarditis; however, this practice is supported by data from studies suggesting that patients with a very low risk of endocarditis (in whom echocardiography is not necessary) can be identified. 20, 35 Moreover, during the follow-up of patients, we did not observe recurrences due to missed endocarditis. A strength of this study is the natural experiment that emerged as a consequence of hospital restructuring that allowed a comparison of different interventions for the management of SAB.
Conclusions
A structured intervention performed by an IDS, based on six quality indicators and that requires ,1 h per patient, improved adherence to the bundle beyond IDS unsolicited consultation. An adherence .75% to the bundle was identified as a modifiable factor associated with a decrease in the mortality at 14 and 30 days in patients with SAB. Experts in infectious diseases should consider using a checklist with these indicators so as not to forget them when attending to patients with SAB. Data shown are number of deaths/number exposed (%).
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